我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
25
2 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
已完成
14
56.0%
尚未招募
2
8.0%
招募中
6
24.0%
Unknown
1
4.0%
暂无批准数据
- Olomorasib combined with pembrolizumab demonstrated a 77% overall response rate in first-line NSCLC patients with KRAS G12C mutations, regardless of PD-L1 expression. - In previously treated NSCLC patients, the combination therapy achieved a 40% overall response rate and an 88% disease control rate. - Common adverse events included diarrhea, fatigue, and increased ALT levels, with manageable safety profiles observed across both cohorts. - A global registrational trial, SUNRAY-01 (NCT06119581), is underway to further evaluate the combination in first-line KRAS G12C-mutated NSCLC.
